Northwest Biotherapeutics, Inc. Completes Acquisition of Advent BioServices Ltd.

Northwest Biotherapeutics, Inc. has completed the acquisition of Advent BioServices Ltd., a UK-based contract development and manufacturing organization (CDMO), from Toucan Holdings LLC. This acquisition, effective October 24, 2025, integrates Advent, previously a service provider for the Company's DCVax® product platform, as a wholly owned subsidiary. The acquisition involves a purchase price of approximately $1.9 million (£1.4 million) and the assumption of approximately $8.3 million in outstanding accounts payable owed by the Company to Advent for pre-acquisition services. An additional $0.7 million in accounts payable for non-Company matters was retained by the Seller. Installment payments are to be made over two years, starting three months after the closing date, with an annual interest rate of 7.5%, and potential acceleration upon regulatory approval of the DCVax®-L product. As part of the transaction, Northwest Biotherapeutics received back 12 million shares of its common stock and 5.5 million stock options previously issued to Advent, which were subsequently retired and cancelled. The acquisition was deemed a related party transaction due to the involvement of Linda Powers, Chairperson, CEO, and President of Northwest Biotherapeutics, who is the controlling member of the Seller. The transaction was approved in accordance with the Company's related-party transaction policies. The SEC granted a waiver from certain financial statement and pro forma information requirements under Regulation S-X.